Can Ceftazidime/Avibactam, Aztreonam, or Linezolid Cause Pancytopenia?
Yes, linezolid can cause pancytopenia and other cytopenias, while ceftazidime/avibactam and aztreonam are not associated with pancytopenia.
Linezolid and Hematologic Toxicity
Linezolid carries a significant risk of myelosuppression including pancytopenia, thrombocytopenia, anemia, and neutropenia. The FDA drug label explicitly warns that myelosuppression has been reported in patients receiving linezolid, and when discontinued, hematologic parameters typically rise toward pretreatment levels 1. This is a well-established, dose- and time-dependent adverse effect.
Key Clinical Features of Linezolid-Induced Cytopenias:
- Time course: Cytopenias typically develop after 2+ weeks of therapy, though thrombocytopenia can occur earlier 2, 3
- Reversibility: Generally reversible upon discontinuation, though recovery may take several days after reaching nadir 4
- Severity: Can range from isolated thrombocytopenia to complete pancytopenia 5, 4, 6
- Mechanism: Likely related to mitochondrial ribosomal toxicity, similar to chloramphenicol 4
Monitoring Requirements:
Complete blood counts should be monitored weekly in all patients receiving linezolid 1. More frequent monitoring is warranted for:
- Treatment duration >2 weeks
- Pre-existing myelosuppression
- Concomitant bone marrow suppressive drugs
- Chronic infections with prior antibiotic exposure
High-Risk Populations:
The guidelines specifically note that linezolid causes less bone marrow suppression in children than adults 2. However, severe anemia may be more common in patients with preexisting anemia 3. Recent case reports suggest that SGLT-2 inhibitors (like dapagliflozin) may exacerbate linezolid-induced myelosuppression, with two patients developing irreversible pancytopenia when both drugs were used concurrently 5.
When to Discontinue:
Discontinuation should be considered in patients who develop or have worsening myelosuppression 1. The FDA label makes this clear as a primary safety concern.
Ceftazidime/Avibactam
Ceftazidime/avibactam is not associated with pancytopenia. The available evidence from multiple guidelines addressing its use in carbapenem-resistant Enterobacterales infections 7 and recent clinical studies 8, 9, 10 does not identify hematologic toxicity as a concern. One study specifically noted that nephrotoxicity (15% of patients) was attributed to concomitant aminoglycosides or colistin, not ceftazidime/avibactam 8.
Aztreonam
Aztreonam does not cause pancytopenia. The guidelines note that aztreonam does not cross-react with other β-lactams except ceftazidime 11, and it is frequently used in combination with ceftazidime/avibactam for metallo-β-lactamase-producing organisms 7. No hematologic toxicity is mentioned in any of the guideline or research evidence. A drug interaction study confirmed that the pharmacokinetics of linezolid or aztreonam are not altered when administered together, with no mention of additive hematologic effects 1.
Clinical Bottom Line:
- Linezolid: Yes, causes pancytopenia (thrombocytopenia > anemia > neutropenia). Monitor CBC weekly. Consider discontinuation if cytopenias develop.
- Ceftazidime/avibactam: No association with pancytopenia
- Aztreonam: No association with pancytopenia
Common Pitfall:
Do not confuse linezolid's well-documented myelosuppression with the safety profiles of ceftazidime/avibactam or aztreonam. If a patient on multiple antibiotics develops pancytopenia, linezolid is the likely culprit if present in the regimen.